Abstract
FT-207, a newly developed anti-metabolite, has been given orally for treatment of 28 cases of malignant tumors of the head and neck regions.
The treatment was composed of three modes of cancer therapy;
1) administration of FT-207 alone,
2) combined therapy of FT-207 with irradiation,
3) chemotherapy of FT-207 following irradiation.
The following results were obtained;
the agent appeared to be effective in 56% of all cases, including 67% of fresh cases and 50% of recurrent ones. In particular, it was markedly effective in cases who were treated concurrently with chemotherapy of FT-207 and irradiation, so that the radiationsensitizing effect of FT-207 was strongly suggested.
In histopathology of these lesions, it was efficacious not only in cases of adenocarcinoma which had been reported by previous authors, but also in those of squamous cell carcinoma.
The mild side effects were seen in 5 cases who presented anorexia and/or stomatoglossitis without blood disturbance or others.
